File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recent advances in pharmacological treatment of psychosis in late life

TitleRecent advances in pharmacological treatment of psychosis in late life
Authors
Issue Date2011
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.co-psychiatry.com
Citation
Current Opinion In Psychiatry, 2011, v. 24 n. 6, p. 455-460 How to Cite?
AbstractPurpose of review: Psychosis is among the most frequent psychiatric symptoms in late life. Treatment of late life psychosis is often challenging because of age-related changes, physical comorbidities and frailty of older adults. The present study aims at reviewing recent literature on pharmacological treatment of psychosis in the older population. RECENT FINDINGS: Recent studies show that antipsychotics remain the mainstay of treatment for older adults with psychosis. Although the efficacies of both typical and atypical antipsychotics have been demonstrated in older adults with schizophrenia, delirium and Parkinson's disease psychosis, there is a growing body of data favoring atypical antipsychotics. However, most of the evidence is not based on rigorously conducted trials. In addition, the use of antipsychotic medication in managing psychosis associated with dementia has declined significantly with the recognition of its serious adverse effects in this vulnerable population. A recent study suggests that effective alternative treatments are yet to be developed. SUMMARY: Studies have demonstrated the clinical benefits of antipsychotics in older people with psychosis. The potential benefits from the use of antipsychotics must be weighed against their adverse effects. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/171969
ISSN
2015 Impact Factor: 3.789
2015 SCImago Journal Rankings: 1.651
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, WCen_HK
dc.contributor.authorLam, LCWen_HK
dc.contributor.authorChen, EYHen_HK
dc.date.accessioned2012-10-30T06:19:00Z-
dc.date.available2012-10-30T06:19:00Z-
dc.date.issued2011en_HK
dc.identifier.citationCurrent Opinion In Psychiatry, 2011, v. 24 n. 6, p. 455-460en_HK
dc.identifier.issn0951-7367en_HK
dc.identifier.urihttp://hdl.handle.net/10722/171969-
dc.description.abstractPurpose of review: Psychosis is among the most frequent psychiatric symptoms in late life. Treatment of late life psychosis is often challenging because of age-related changes, physical comorbidities and frailty of older adults. The present study aims at reviewing recent literature on pharmacological treatment of psychosis in the older population. RECENT FINDINGS: Recent studies show that antipsychotics remain the mainstay of treatment for older adults with psychosis. Although the efficacies of both typical and atypical antipsychotics have been demonstrated in older adults with schizophrenia, delirium and Parkinson's disease psychosis, there is a growing body of data favoring atypical antipsychotics. However, most of the evidence is not based on rigorously conducted trials. In addition, the use of antipsychotic medication in managing psychosis associated with dementia has declined significantly with the recognition of its serious adverse effects in this vulnerable population. A recent study suggests that effective alternative treatments are yet to be developed. SUMMARY: Studies have demonstrated the clinical benefits of antipsychotics in older people with psychosis. The potential benefits from the use of antipsychotics must be weighed against their adverse effects. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.en_HK
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.co-psychiatry.comen_HK
dc.relation.ispartofCurrent Opinion in Psychiatryen_HK
dc.subject.meshAgeden_US
dc.subject.meshAntipsychotic Agents - Therapeutic Useen_US
dc.subject.meshDelirium - Psychologyen_US
dc.subject.meshDementia - Psychologyen_US
dc.subject.meshHumansen_US
dc.subject.meshParkinson Disease - Psychologyen_US
dc.subject.meshPsychotic Disorders - Drug Therapyen_US
dc.subject.meshSchizophrenia - Drug Therapyen_US
dc.titleRecent advances in pharmacological treatment of psychosis in late lifeen_HK
dc.typeArticleen_HK
dc.identifier.emailChan, WC: waicchan@hku.hken_HK
dc.identifier.emailChen, EYH: eyhchen@hku.hken_HK
dc.identifier.authorityChan, WC=rp01687en_HK
dc.identifier.authorityChen, EYH=rp00392en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/YCO.0b013e32834a3f47en_HK
dc.identifier.pmid21799414-
dc.identifier.scopuseid_2-s2.0-80053386363en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80053386363&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume24en_HK
dc.identifier.issue6en_HK
dc.identifier.spage455en_HK
dc.identifier.epage460en_HK
dc.identifier.isiWOS:000295321400001-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChan, WC=16400525900en_HK
dc.identifier.scopusauthoridLam, LCW=7201984627en_HK
dc.identifier.scopusauthoridChen, EYH=7402315729en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats